Single Center Characterization of a Cohort of Salivary Gland Carcinomas
Salivary gland cancer (SGC) is a rare cancer that can present a diagnostic challenge to pathologists, with emerging, but still limited options for the treatment of recurrent/metastatic disease. We aimed to characterize the cohort of salivary gland cancers in our institute and generate a tissue micro...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-08-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/14/9/1089 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850260599457447936 |
|---|---|
| author | Ria Winkelmann Maja Weißgerber Peter J. Wild Julia Bein Maximilian Fleischmann Melanie Demes Panagiotis Balermpas Andreas Loth Katrin Bankov Jens von der Grün |
| author_facet | Ria Winkelmann Maja Weißgerber Peter J. Wild Julia Bein Maximilian Fleischmann Melanie Demes Panagiotis Balermpas Andreas Loth Katrin Bankov Jens von der Grün |
| author_sort | Ria Winkelmann |
| collection | DOAJ |
| description | Salivary gland cancer (SGC) is a rare cancer that can present a diagnostic challenge to pathologists, with emerging, but still limited options for the treatment of recurrent/metastatic disease. We aimed to characterize the cohort of salivary gland cancers in our institute and generate a tissue microarray (TMA) with clinical data available for immunohistochemical analysis. We extracted the cases of salivary gland cancers in our institute and generated a TMA with 72 patients between 2002 and 2017 with sufficient paraffin block material. Follow-up data were present for all cases. The TMA was stained with three p53 antibodies as well as MSH2, MSH6, PMS2 and MLH1 antibodies. Additionally, we applied fragment analysis based on the Bethesda panel, and the IdyllaTM MSI test to cases with expression loss of any of the mismatch repair proteins (MMR-P) according to our immunohistochemistry (IHC). The investigated cohort shows that pT and pN stage are the only factors independently associated with survival, according to our multivariate analysis (<i>p</i> = 0.037 and <i>p</i> = 0.014). In univariate analysis, risk factors identified in our cohort were also age (<i>p</i> = 0.015), (lympho-) vascular invasion (<i>p</i> = 0.002 and <i>p</i> = 0.003) and risk stratification (<i>p</i> = 0.037). The p53 protein investigated by three antibodies showed no statistically significant association with survival or other tumor characteristics in the investigated cohort. According to MMR-P IHC, six cases of SGC showed an aberrant IHC phenotype. Additional IdyllaTM MSI test and fragment length analysis failed to confirm microsatellite instability. The pT and pN stage are the most important factors for survival in our cohort. In our cohort, antibodies directed against the protein p53 did not contribute to clinical decision-making and were not correlated with any known clinical characteristics. MSI appears to be insignificant in SGCs. Larger cohorts are needed for verification. |
| format | Article |
| id | doaj-art-0e1c9b239de44339848e511c52c52aba |
| institution | OA Journals |
| issn | 2075-1729 |
| language | English |
| publishDate | 2024-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj-art-0e1c9b239de44339848e511c52c52aba2025-08-20T01:55:37ZengMDPI AGLife2075-17292024-08-01149108910.3390/life14091089Single Center Characterization of a Cohort of Salivary Gland CarcinomasRia Winkelmann0Maja Weißgerber1Peter J. Wild2Julia Bein3Maximilian Fleischmann4Melanie Demes5Panagiotis Balermpas6Andreas Loth7Katrin Bankov8Jens von der Grün9Dr. Senckenberg Institute of Pathology, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyDr. Senckenberg Institute of Pathology, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyDr. Senckenberg Institute of Pathology, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyDr. Senckenberg Institute of Pathology, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyDepartment of Radiation Oncology, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt, GermanyDr. Senckenberg Institute of Pathology, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyDepartment of Radiation Oncology, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt, GermanyDepartment of Otorhinolarygology, Goethe University Frankfurt am Main, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyDr. Senckenberg Institute of Pathology, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyDepartment of Radiation Oncology, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt, GermanySalivary gland cancer (SGC) is a rare cancer that can present a diagnostic challenge to pathologists, with emerging, but still limited options for the treatment of recurrent/metastatic disease. We aimed to characterize the cohort of salivary gland cancers in our institute and generate a tissue microarray (TMA) with clinical data available for immunohistochemical analysis. We extracted the cases of salivary gland cancers in our institute and generated a TMA with 72 patients between 2002 and 2017 with sufficient paraffin block material. Follow-up data were present for all cases. The TMA was stained with three p53 antibodies as well as MSH2, MSH6, PMS2 and MLH1 antibodies. Additionally, we applied fragment analysis based on the Bethesda panel, and the IdyllaTM MSI test to cases with expression loss of any of the mismatch repair proteins (MMR-P) according to our immunohistochemistry (IHC). The investigated cohort shows that pT and pN stage are the only factors independently associated with survival, according to our multivariate analysis (<i>p</i> = 0.037 and <i>p</i> = 0.014). In univariate analysis, risk factors identified in our cohort were also age (<i>p</i> = 0.015), (lympho-) vascular invasion (<i>p</i> = 0.002 and <i>p</i> = 0.003) and risk stratification (<i>p</i> = 0.037). The p53 protein investigated by three antibodies showed no statistically significant association with survival or other tumor characteristics in the investigated cohort. According to MMR-P IHC, six cases of SGC showed an aberrant IHC phenotype. Additional IdyllaTM MSI test and fragment length analysis failed to confirm microsatellite instability. The pT and pN stage are the most important factors for survival in our cohort. In our cohort, antibodies directed against the protein p53 did not contribute to clinical decision-making and were not correlated with any known clinical characteristics. MSI appears to be insignificant in SGCs. Larger cohorts are needed for verification.https://www.mdpi.com/2075-1729/14/9/1089salivary gland neoplasmssurvivalMSIimmunohistochemistryp53Bethesda panel |
| spellingShingle | Ria Winkelmann Maja Weißgerber Peter J. Wild Julia Bein Maximilian Fleischmann Melanie Demes Panagiotis Balermpas Andreas Loth Katrin Bankov Jens von der Grün Single Center Characterization of a Cohort of Salivary Gland Carcinomas Life salivary gland neoplasms survival MSI immunohistochemistry p53 Bethesda panel |
| title | Single Center Characterization of a Cohort of Salivary Gland Carcinomas |
| title_full | Single Center Characterization of a Cohort of Salivary Gland Carcinomas |
| title_fullStr | Single Center Characterization of a Cohort of Salivary Gland Carcinomas |
| title_full_unstemmed | Single Center Characterization of a Cohort of Salivary Gland Carcinomas |
| title_short | Single Center Characterization of a Cohort of Salivary Gland Carcinomas |
| title_sort | single center characterization of a cohort of salivary gland carcinomas |
| topic | salivary gland neoplasms survival MSI immunohistochemistry p53 Bethesda panel |
| url | https://www.mdpi.com/2075-1729/14/9/1089 |
| work_keys_str_mv | AT riawinkelmann singlecentercharacterizationofacohortofsalivaryglandcarcinomas AT majaweißgerber singlecentercharacterizationofacohortofsalivaryglandcarcinomas AT peterjwild singlecentercharacterizationofacohortofsalivaryglandcarcinomas AT juliabein singlecentercharacterizationofacohortofsalivaryglandcarcinomas AT maximilianfleischmann singlecentercharacterizationofacohortofsalivaryglandcarcinomas AT melaniedemes singlecentercharacterizationofacohortofsalivaryglandcarcinomas AT panagiotisbalermpas singlecentercharacterizationofacohortofsalivaryglandcarcinomas AT andreasloth singlecentercharacterizationofacohortofsalivaryglandcarcinomas AT katrinbankov singlecentercharacterizationofacohortofsalivaryglandcarcinomas AT jensvondergrun singlecentercharacterizationofacohortofsalivaryglandcarcinomas |